

## Ibrance® (palbociclib) – New formulation approval

- On November 1, 2019, the <u>FDA approved</u> an oral tablet formulation of Pfizer's <u>lbrance (palbociclib)</u>, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
  - An aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or
  - <u>Fulvestrant</u> in patients with disease progression following endocrine therapy.
- Ibrance was previously approved as a <u>capsule formulation</u>. The tablets and capsules share the same indication.
  - Ibrance tablets can be taken orally with or without food whereas the capsules had to be taken with food.
- Warnings and precautions of Ibrance include neutropenia, interstitial lung disease/pneumonitis, and embryo-fetal toxicity.
- The most common adverse reactions (≥ 10%) with Ibrance use were neutropenia, infections, leukopenia, fatigue, nausea, stomatitis, anemia, alopecia, diarrhea, thrombocytopenia, rash, vomiting, decreased appetite, asthenia, and pyrexia.
- The recommended dosage of Ibrance is 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.
  - Refer to the drug labels for the aromatase inhibitor used or fulvestrant for additional dosing recommendations for those products.
- Pfizer's launch plans for the tablet formulation are pending. The new formulation will be available as 75 mg, 100 mg, and 125 mg tablets.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.